Adaptimmune Therapeutics PLC
(NAS:ADAP)
$
0.7969
0.02 (2.57%)
Market Cap: 203.80 Mil
Enterprise Value: 36.36 Mil
PE Ratio: 0
PB Ratio: 2.11
GF Score: 62/100 Adaptimmune Therapeutics PLC Strategic Collaboration with Genentech Inc Presentation Transcript
Sep 09, 2021 / 12:00PM GMT
Release Date Price:
$6.21
(-0.64%)
Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
Presentation
Sep 09, 2021 / 12:00PM GMT
=====================
Corporate Participants
=====================
* Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
* Helen Katrina Tayton-Martin
Adaptimmune Therapeutics plc - Co-Founder & Chief Business Officer
* Joanna Brewer
Adaptimmune Therapeutics plc - SVP of Allogeneic Research
* William C. Bertrand
Adaptimmune Therapeutics plc - COO
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot